Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia.
Vreden National Medical Research Center of Traumatology and Orthopedics, 195427 St. Petersburg, Russia.
Int J Mol Sci. 2024 Oct 20;25(20):11279. doi: 10.3390/ijms252011279.
Sortase A (SrtA) of has long been shown to be a relevant molecular target for antibacterial development. Moreover, the designed SrtA inhibitors act via the antivirulence mechanism, potentially causing less evolutional pressure and reduced antimicrobial resistance. However, no marketed drugs or even drug candidates have been reported until recently, despite numerous efforts in the field. SrtA has been shown to be a tough target for rational structure-based drug design (SBDD), which hampers the regular development of small-molecule inhibitors using the available arsenal of drug discovery tools. Recently, several oligopeptides resembling the sorting sequence LPxTG (Leu-Pro-Any-Thr-Gly) of the native substrates of SrtA were reported to be active in the micromolar range. Despite the good experimental design of those works, their molecular modeling parts are still not convincing enough to be used as a basis for a rational modification of peptidic inhibitors. In this work, we propose to use the ensemble docking approach, in which the relevant SrtA conformations are extracted from the molecular dynamics simulation of the LPRDA (Leu-Pro-Arg-Asp-Ala)-SrtA complex, to effectively represent the most significant and diverse target conformations. The developed protocol is shown to describe the known experimental data well and then is applied to a series of new peptidomimetic molecules resembling the active oligopeptide structures reported previously in order to prioritize structures from this work for further synthesis and activity testing. The proposed approach is compared to existing alternatives, and further directions for its development are outlined.
金黄色酿脓葡萄球菌的 Sortase A(SrtA)长期以来一直被认为是抗菌药物开发的一个相关分子靶标。此外,设计的 SrtA 抑制剂通过抗毒力机制起作用,可能会引起较少的进化压力和减少抗菌药物耐药性。然而,尽管该领域进行了大量努力,直到最近才报道了没有上市的药物甚至药物候选物。SrtA 一直被认为是合理基于结构的药物设计(SBDD)的一个艰巨目标,这阻碍了使用现有的药物发现工具库来常规开发小分子抑制剂。最近,据报道,几种类似于 SrtA 的天然底物的排序序列 LPxTG(亮氨酸-脯氨酸-任何-苏氨酸-甘氨酸)的寡肽在微摩尔范围内具有活性。尽管这些工作的实验设计良好,但它们的分子建模部分仍然不够令人信服,无法作为合理修饰肽类抑制剂的基础。在这项工作中,我们建议使用集合对接方法,其中从 LPRDA(亮氨酸-脯氨酸-精氨酸-天冬氨酸-丙氨酸)-SrtA 复合物的分子动力学模拟中提取相关的 SrtA 构象,以有效地表示最重要和最具多样性的靶标构象。所开发的方案被证明可以很好地描述已知的实验数据,然后应用于一系列类似于先前报道的活性寡肽结构的新型肽模拟分子,以便为进一步的合成和活性测试优先考虑这项工作中的结构。该方法与现有替代方法进行了比较,并概述了进一步的发展方向。